NASDAQ$QURE
uniQure NV · Q2 2020 earnings
Q2 2020 earnings · · Investor relations
Briefing
Reported financial results and highlighted recent company progress.
uniQure reported its financial results for the second quarter of 2020. They entered into an exclusive global license agreement with CSL Behring for their gene therapy candidate for hemophilia B and completed the first patient dosing in a Phase I/II clinical trial of AMT-130 in Huntington’s Disease.
- Entered into Exclusive Global License Agreement with CSL Behring for Development and Commercialization of uniQure’s Gene Therapy Candidate for Hemophilia B.
- Completed First Patient Dosing in Phase I/II Clinical Trial of AMT-130 in Huntington’s Disease.
- Cash and cash equivalents totaled $314.3 million as of June 30, 2020.
- uniQure is eligible following regulatory approval to receive more than $2 billion of economics from CSL Behring, including upfront cash, milestone, and royalty payments
Headline financials
Revenue & EPS history
uniQure · Revenue · Quarterly
$1.54M
Forward guidance
This press release contains forward-looking statements. uniQure’s actual results could differ materially from those anticipated in these forward-looking statements for many reasons.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q2 2020
+1.0%
Avg return
Earnings day
+2.2%
Avg return
5 days after
+2.6%
Avg return
30 days after
59%
27 / 46 earnings
Positive
+47.1%
Q2 2015
Best reaction
-32.7%
Q4 2025
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +2.5% | +34.0% | +35.5% | |
| Q4 2025 | -32.7% | -8.7% | +8.1% | |
| Q3 2025 | -6.0% | +7.5% | -27.5% | |
| Q1 2025 | +3.3% | +17.0% | +15.8% | |
| Q4 2024 | +3.4% | -2.9% | +6.9% | |
| Q3 2024 | +28.8% | +40.1% | +18.5% | |
| Q2 2024 | -4.6% | -1.3% | -23.6% | |
| Q1 2024 | +3.6% | +4.2% | +12.5% | |
| Q4 2023 | -14.8% | -23.6% | -23.0% | |
| Q3 2023 | +6.5% | -0.8% | +19.5% | |
| Q2 2023 | -3.0% | -9.2% | -16.0% | |
| Q1 2023 | +2.7% | +1.2% | -3.8% | |
| Q4 2022 | +5.0% | +6.2% | +1.3% | |
| Q3 2022 | +4.4% | +0.1% | +38.2% | |
| Q2 2022 | -25.5% | -20.2% | -18.4% | |
| Q1 2022 | +6.6% | -2.0% | -5.2% | |
| Q4 2021 | +5.9% | +13.0% | +4.5% | |
| Q3 2021 | -0.3% | +7.1% | +2.2% | |
| Q2 2021 | +8.5% | +11.5% | +10.7% | |
| Q1 2021 | +0.7% | -0.3% | +12.3% | |
| Q4 2020 | -2.0% | -11.5% | -8.2% | |
| Q3 2020 | -10.6% | -7.0% | +7.0% | |
| Q2 2020 | +10.7% | +12.0% | +3.7% | |
| Q1 2020 | +1.0% | -3.2% | +6.6% | |
| Q4 2019 | +1.5% | +1.4% | -11.3% | |
| Q3 2019 | -0.8% | +3.9% | +13.4% | |
| Q2 2019 | -8.5% | -9.1% | -17.1% | |
| Q1 2019 | -2.0% | +2.4% | +5.4% | |
| Q4 2018 | +7.7% | +11.8% | +12.1% | |
| Q3 2018 | +9.0% | +0.5% | +20.1% | |
| Q2 2018 | +6.6% | +9.3% | +21.9% | |
| Q1 2018 | -0.3% | -3.2% | +15.7% | |
| Q4 2017 | -13.5% | -17.2% | +16.9% | |
| Q3 2017 | -2.6% | +4.4% | +4.4% | |
| Q2 2017 | +7.2% | +5.1% | +4.8% | |
| Q1 2017 | +2.3% | +3.3% | +6.6% | |
| Q4 2016 | +1.0% | -3.1% | -10.5% | |
| Q3 2016 | -6.2% | -3.9% | -20.6% | |
| Q1 2016 | +11.8% | +16.8% | -38.5% | |
| Q3 2015 | -12.0% | — | — | |
| Q1 2015 | -2.3% | — | — | |
| Q2 2015 | +47.1% | — | — | |
| Q4 2014 | -7.5% | — | — | |
| Q2 2014 | +10.9% | — | — | |
| Q4 2013 | +3.0% | — | — | |
| Q1 2014 | +0.4% | — | — | |
| Q3 2013 | — | — | — | |
| Q2 2013 | — | — | — | |
| Q1 2013 | — | — | — | |
| Q4 2012 | — | — | — | |
| Q3 2012 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro